Study finds Paxlovid treatment does not reduce risk of long COVID

A team of researchers from UC San Francisco has found that Paxlovid (Nirmatrelvir-ritonavir) did not reduce the risk of developing long COVID for vaccinated, non-hospitalized individuals during their first COVID-19 infection. They also found a higher proportion of individuals with acute symptoms rebound and test-positivity than previously reported.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart